Pages that link to "Q37217221"
Jump to navigation
Jump to search
The following pages link to Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia (Q37217221):
Displaying 12 items.
- Combating antimicrobial resistance: policy recommendations to save lives (Q24632857) (← links)
- Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America (Q29616084) (← links)
- Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (Q34165319) (← links)
- Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia (Q35215307) (← links)
- Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies (Q35867451) (← links)
- A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin (Q36551335) (← links)
- In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). (Q38035808) (← links)
- Current treatment of Gram-positive infections: from experimental models to clinical experience after approval of new drugs (Q42743432) (← links)
- Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia? (Q48023992) (← links)
- AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States (Q50916931) (← links)
- Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study (Q53154931) (← links)
- Endocan, a Risk Factor for Developing Acute Respiratory Distress Syndrome among Severe Pneumonia Patients (Q64090167) (← links)